Status:

UNKNOWN

Tucidinostat Plus Apatinib for Advanced Osteosarcoma

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions:

Osteosarcoma

Eligibility:

All Genders

10-75 years

Phase:

PHASE2

Brief Summary

This phase II study was designed to assess the efficacy and safety of the combination of Apatinib, Tucidinostat (chidamide), a histone deacetylase inhibitor in relapsed or refractory osteosarcoma pati...

Eligibility Criteria

Inclusion

  • Age ≥10 years, ≤ 75 years;
  • Histologically confirmed Advanced classic osteosarcoma with unresectable recurrence or metastatic disease ;
  • Prior treatment consisted of standard chemotherapy agents including doxorubicin, cisplatin, methotrexate, and ifosfamide;
  • Eastern Collaborative Oncology Group (ECOG) 0\~2;
  • Tumor size is measurable according to RECIST1.1 criteria;
  • Adequate organ function;
  • Life expectancy is more than 3 months;
  • Willing and able to provide written informed consent.

Exclusion

  • Previously exposed to histone deacetylase inhibitors or angiogenesis inhibitors;
  • Urine protein≥ ++;
  • FBG\>10mmol/L;
  • Uncontrolled blodd pressure (ystolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 90 mmHg);
  • Known active CNS metastases and/or carcinomatous meningitis;
  • Not able to take medicine orally;
  • Coagulant function abnormality (PT\>16s, APTT\> 43s, TT\>21s, FIB)\<2g/L);
  • Uncontrolled clinically significant systemic diseases, including active infection, unstable angina, angina occurred within 3 months,≥ NYHA II congestive heart failure, myocardial infarction occurred within 6 months, severe arrhythmia, liver, kidney, or metabolic disease;
  • Major surgery received or severe traumatic injury, fracture, or ulcer occurred within 4 weeks of the first dose of study medication.

Key Trial Info

Start Date :

January 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

46 Patients enrolled

Trial Details

Trial ID

NCT06125171

Start Date

January 1 2024

End Date

December 1 2025

Last Update

November 9 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Tucidinostat Plus Apatinib for Advanced Osteosarcoma | DecenTrialz